Outbreak of Legionnaires' disease in immunosuppressed patients at a cancer centre: Usefulness of universal urine antigen testing and early levofloxacin therapy

Clinical Microbiology and Infection

Volumn 13, Issue 11, 2007, Pages 1125-1128

  Gudiol, C ^a   Verdaguer, R ^a   Angeles Dominguez M ^a   Fernandez Sevilla A ^b   Carratala J ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Immunosuppressed patients; Legionnaires' disease; Levofloxacin therapy; Nosocomial outbreak; Pneumonia; Urine antigen testing

Indexed keywords

ANTINEOPLASTIC AGENT; CLARITHROMYCIN; CORTICOSTEROID; CYCLOSPORIN; LEVOFLOXACIN; MACROLIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANTIGEN DETECTION; APLASTIC ANEMIA; ARTICLE; CENTRAL NERVOUS SYSTEM METASTASIS; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; DISSEMINATED CANCER; EARLY INTERVENTION; FEMALE; HIGH RISK POPULATION; HOSPITAL INFECTION; HUMAN; IMMUNOCOMPROMISED PATIENT; LEGIONNAIRE DISEASE; LUNG ASPERGILLOSIS; LUNG CANCER; LYMPHOMA; MALE; MONOTHERAPY; MORTALITY; NEUTROPENIA; PANCREAS CANCER; PRIORITY JOURNAL; URINALYSIS; VIRUS PNEUMONIA;

EID: 35048823464     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2007.01805.x     Document Type: Article

References (14)

1. Benin AL, Benson RF, Besser RE. Trends in Legionnaires' disease, 1980-1998: Declining mortality and new patterns of diagnosis. Clin Infect Dis 2002; 35: 1039-1046.
2. Plouffe JF, Breiman RF, Fields BS et al. Azithromycin in the treatment of Legionella pneumonia requiring hospitalisation. Clin Infect Dis 2003; 37: 1475-1480.
3. Yu VL, Greenberg RN, Zadeikis N et al. Levofloxacin efficacy in the treatment of community-acquired legionellosis. Chest 2004; 125: 2135-2139.
4. Mykietiuk A, Carratalà J, Fernández-Sabé N et al. Clinical outcomes for hospitalized patients with Legionella pneumonia in the antigenuria era: The influence of levofloxacin therapy. Clin Infect Dis 2005; 40: 794-799.
5. Blázquez Garrido MR, Espinosa Parra FJ, Alemany Francés L et al. Antimicrobial chemotherapy for Legionnaires' disease: levofloxacin versus macrolides. Clin Infect Dis 2005; 40: 800-806.
6. SabriàM, Pedro-Botet ML, Gómez J et al. Fluoroquinolones vs macrolides in the treatment of Legionnaires disease. Chest 2005; 128: 1401-1405.
7. Pedro-Botet L, Yu VL. Legionella: Macrolides or quinolones? Clin Microbiol Infect 2006; 12 (suppl 3): 25-30.
8. García-Vidal C, Carratalà J. Current clinical management of Legionnaires' disease. Expert Rev Anti Infect Ther 2006; 4: 995-1004.
9. Schoonmaker D, Heimberger T, Birkhead G. Comparison of ribotyping and restriction enzyme analysis using pulsed-field gel electrophoresis for distinguishing Legionella pneumophila isolates obtained during a nosocomial outbreak. J Clin Microbiol 1992; 30: 1491-1498.
10. Falguera M, Rufí G, Dorca J, Verdaguer R, Gudiol F, Manresa F. Neumonía por Legionella pneumophila en el paciente inmunodeprimido. Enferm Infecc Microbiol Clin 1988; 6: 130-135.
11. Kirby BD, Snyder KM, Meyer RD, Finegold SM. Legionnaires' disease: report of sixty-five nosocomially acquired cases and review of the literature. Medicine 1980; 59: 188-205.
12. Smith RP, Baltch AL, Franke M, Hioe W, Ritz W, Michelsen P. Effect of levofloxacin, erythromycin or rifampicin pre-treatment on growth of Legionella pneumophila in human monocytes. J Antimicrob Chemother 1997; 40: 673-678.
13. Edelstein PH. Antimicrobial chemotherapy for legionnaires' disease: Time for a change. Ann Intern Med 1998; 129: 328-330.
14. Roig J, Rello J. Legionnaires' disease: A rational approach to therapy. J Antimicrob Chemother 2003; 51: 1119-1129.